Highlight
The LifeAfter90 study reveals that among individuals aged 90 and older, carriers of the APOE ɛ4 allele show accelerated decline in executive function despite exceptional longevity, while APOE ɛ2 carriers demonstrate a protective effect with slower decline in verbal episodic memory. These associations persist even after accounting for competing mortality risks, emphasizing the nuanced roles of APOE genotypes in late-life cognition.
Study Background
The apolipoprotein E (APOE) gene is a major genetic determinant of Alzheimer’s disease (AD) risk, with the ɛ4 allele recognized as the strongest genetic risk factor for late-onset AD, and the ɛ2 allele often associated with reduced susceptibility. Although this relationship is well established in younger elderly populations, there is limited understanding of how these genotypes influence cognitive trajectories in those who have achieved exceptional longevity, defined here as individuals aged 90 years and above.
Cognitive decline in advanced age poses a significant public health challenge, compounded by the growing demographic of oldest-old adults worldwide. Understanding genetic contributions to cognitive aging in this population can inform prognostic assessments and potential therapeutic targets, especially given the high variability in cognitive resilience observed among the oldest old.
Study Design
The LifeAfter90 study is an ongoing longitudinal, multiethnic cohort investigation that enrolls individuals aged 90 years and older. APOE genotyping was performed using DNA extracted from saliva samples collected at baseline. Participants were categorized based on APOE genotype as either ɛ4 carriers (genotypes ɛ2/ɛ4, ɛ3/ɛ4, or ɛ4/ɛ4) or non-ɛ4 carriers, and separately as ɛ2 carriers (genotypes ɛ2/ɛ2, ɛ2/ɛ3) or non-ɛ2 carriers.
Three cognitive domains were assessed longitudinally every six months up to 11 visits using the validated Spanish and English Neuropsychological Scales: executive function (EF), semantic memory (SM), and verbal episodic memory (VEM). The cohort included 445 participants (mean baseline age 93 years, range 90–104), representing diverse ethnoracial backgrounds including African American/Black (21%), Asian (22%), Hispanic/Latinx (16%), multiracial/other (9%), and White (32%). Mortality outcomes were recorded over an average 3.9-year follow-up.
To analyze cognitive trajectories, linear mixed-effects (LME) models and joint models combining LME with Cox proportional hazard models were used, the latter to adjust for the competing risk of death. Models were adjusted for age and sex, enabling assessment of the independent association of APOE ɛ4 and ɛ2 alleles with domain-specific cognitive decline.
Key Findings
Among the 445 participants, 20% were APOE ɛ4 carriers and 15% were APOE ɛ2 carriers. During follow-up, 54% of participants died, but neither ɛ4 nor ɛ2 status significantly altered all-cause mortality hazard after adjustment.
Crucially, APOE ɛ4 carriers experienced a significantly faster decline in executive function compared with non-ɛ4 carriers (joint model β = -0.07; 95% CI, -0.12 to -0.02). This indicates a consistent negative impact of the ɛ4 allele on aspects of cognition related to planning, flexibility, and working memory even in the oldest-old population. However, ɛ4 status did not significantly influence semantic memory (β = -0.03; 95% CI, -0.08 to 0.02) or verbal episodic memory decline (β = -0.01; 95% CI, -0.08 to 0.05).
Conversely, APOE ɛ2 carriers showed a protective association with verbal episodic memory decline, exhibiting a slower rate of decline over time (β = 0.07; 95% CI, 0.00 to 0.15) compared with non-ɛ2 carriers. No statistically significant differences were observed in executive function (β = 0.01; 95% CI, -0.05 to 0.08) or semantic memory (β = 0.01; 95% CI, -0.05 to 0.08) decline related to ɛ2 carriage.
Results from LME models alone closely aligned with those from joint models, underscoring the robustness of the findings despite the high competing mortality risk in this elderly cohort.
Expert Commentary
The LifeAfter90 study provides pivotal evidence that the deleterious effects of APOE ɛ4 on executive function—a key domain for daily functioning—remain evident in nonagenarians and older adults with exceptional longevity. This suggests that while these individuals survive to advanced age, APOE ɛ4 carriers are nonetheless vulnerable to cognitive decline particularly affecting frontal lobe-dependent processes.
The protective effect of APOE ɛ2 on verbal episodic memory aligns with prior literature suggesting ɛ2’s role in neuroprotection and cognitive resilience, potentially through mechanisms such as enhanced lipid metabolism or reduced amyloid-beta accumulation.
Limitations include potential survivor bias inherent in the oldest-old cohorts and the challenge of generalizing findings to less diverse or younger elderly populations. Furthermore, the observational design precludes causal inferences. The multiethnic composition, however, enhances the study’s relevance across diverse demographic groups.
Conclusion
This longitudinal investigation confirms that the APOE ɛ4 allele is associated with accelerated executive function decline in individuals aged 90 and above, even after adjusting for mortality risks. In contrast, APOE ɛ2 carriage is linked with preservation of verbal episodic memory in this exceptional longevity cohort.
These findings deepen our understanding of genetic contributions to cognitive aging beyond the conventional elderly populations and underscore the need for genotype-stratified approaches in predicting and managing cognitive decline in the oldest-old. Further research exploring biological pathways underlying these genotype-specific effects may inform targeted interventions to promote cognitive health in advanced age.
Funding and ClinicalTrials.gov
Details regarding study funding and registration were not provided in the summary but are essential for transparency and reproducibility in ongoing research contexts.
References
- Colbeth HL, Posis AIB, Rizvi BM, et al. Role of APOE ɛ4 and ɛ2 With Longitudinal Cognitive Decline Among Those With Exceptional Longevity: The LifeAfter90 Study. Neurology. 2026 Oct 16;107(9):e218596. PMID: 42886871.
- Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016;94(7):739-746.
- Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993 Aug 13;261(5123):921-3.
- Huang Y. Mechanisms linking apolipoprotein E isoforms with Alzheimer’s disease. Curr Alzheimer Res. 2010;7(5):499-505.
